Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
AM

AMGNStock

Nasdaq Global Select Market · Healthcare · US

$443.89 last close 2026-11-18
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment AMGN's does — no target price to set, unlike a price alert.

Near limit Ratio screen, 4 of 7 decided standards passing. Dow Jones Islamic, MSCI Islamic M-Series, S&P Shariah are within 3 points of their line. If they all crossed, the majority verdict would move from Compliant to Not compliant. What would change it

Sharia status
COMPLIANT
Per our in-house ratio engine
1 of 7 pass our own screen — the standards disagree
Purification 0.00% *HTR non-permissible income 1.11%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 2 bearish
34
of 100
Setup confidence — system conviction, not win probabilityF

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure1 of 5 timeframes bullish · 43.5% aligned
VWAPPrice below VWAP ($458.37)
VolumeRelative volume 2.3× the 20-day average
Momentum10-day rate of change -5.5%
Overall readNEUTRAL — No Edge

AMGN is currently considered halal (Sharia-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Wall Street consensus
HOLD
43 analysts
Institutional own.
85.1%
of shares
Momentum (10d)
-5.5%
rate of change
SMC grade
F · 34
43.5% aligned
0.00% *
Purification ratio (secondary provider, uncertain)
1.11%
Non-permissible income — HTR, from filings (2025-12-31)
F · 34
SMC grade — 43.5% timeframe alignment
-5.5%
Rate of change (10d)
HOLD
Wall Street consensus (43)
85.1%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to AMGN’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 18, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $251.9B as of 2026-11-16. At the 2026-11-18 close it is about $244.5B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 22.1% (21.4% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 5.4% (5.2% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 21.44% 30.00% Pass(8.6pp buffer)
Interest-bearing investments 5.24% 30.00% Pass(24.8pp buffer)
Non-permissible income 1.11% 5.00% Pass(3.9pp buffer)
Usmani Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 56.23% 33.00% Fail(23.2pp over)
Interest-bearing investments 13.73% 33.00% Pass(19.3pp buffer)
Non-liquid assets 75.49% at least 20.00% Pass(55.5pp above the floor)
Non-permissible income 1.11% 5.00% Pass(3.9pp buffer)
MSCI Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 56.23% 33.33% Fail(22.9pp over)
Cash + interest-bearing securities 13.73% 33.33% Pass(19.6pp buffer)
Accounts receivable 24.51% 33.33% Pass(8.8pp buffer)
Non-permissible income 1.11% 5.00% Pass(3.9pp buffer)
FTSE Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 56.23% 33.33% Fail(22.9pp over)
Cash + interest-bearing securities 13.73% 33.33% Pass(19.6pp buffer)
Accounts receivable 24.51% 50.00% Pass(25.5pp buffer)
Non-permissible income 1.11% 5.00% Pass(3.9pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 29.45% 33.00% Pass(3.6pp buffer)
Cash + interest-bearing securities 7.19% 33.00% Pass(25.8pp buffer)
Accounts receivable 5.64% 33.00% Pass(27.4pp buffer)
Non-permissible income 1.11% 5.00% Pass(3.9pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 30.82% 33.00% Pass(2.2pp buffer)
Cash + interest-bearing securities 7.53% 49.00% Pass(41.5pp buffer)
Accounts receivable 5.91% 49.00% Pass(43.1pp buffer)
Non-permissible income 1.11% 5.00% Pass(3.9pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 30.82% 33.33% Pass(2.5pp buffer)
Cash + interest-bearing securities 7.53% 33.33% Pass(25.8pp buffer)
Accounts receivable 13.43% 49.00% Pass(35.6pp buffer)
Non-permissible income 1.11% 5.00% Pass(3.9pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

S&P Shariah Indices (% of 36-mo avg market cap)debt ratio 2.2pts
MSCI Islamic M-Series (% of 36-mo avg market cap)debt ratio 2.5pts
Dow Jones Islamic Market (% of 24-mo avg market cap)debt ratio 3.6pts
Usmani (% of total assets)debt ratio 23.2pts
MSCI Islamic Index (% of total assets)debt ratio 22.9pts
FTSE Shariah Global Equity Index Series (% of total assets)debt ratio 22.9pts

The numbers the ratios are built from

Read from AMGN's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $36.8B 2025-12-31 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtShort and long-term borrowings $54.0B 2026-09-30 LongTermDebtNoncurrent, LongTermDebtCurrent
Cash and interest-bearing securitiesCash, equivalents and marketable securities $13.2B 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $96.0B 2026-09-30 Assets
Market capDenominator for AAOIFI $251.9B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $166.3B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $173.9B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $408.0M 2025-12-31 InvestmentIncomeInterest

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Income statement as of 2025-12-31. Screened 2026-11-16.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$96.0B
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$54.0B
    LongTermDebtNoncurrent, LongTermDebtCurrent · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$13.2B
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · balance sheet as of 2026-09-30
  • Receivables$10.4B
    AccountsReceivableNetCurrent · balance sheet as of 2026-09-30
  • Revenue$36.8B
    RevenueFromContractWithCustomerExcludingAssessedTax · income statement as of 2025-12-31
  • Interest income (non-permissible)$408.0M
    InvestmentIncomeInterest · income statement as of 2025-12-31
  • Market cap$251.9B
    Market-data quote at screen time, 2026-11-16 · not a filing figure, so no link

What changed, and when

Verdict history for AMGN. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-11-16 Fail → Pass filing re-screen
  • 2026-09-07 Non Compliant → Compliant watchlist re-scan

Tracked since 2026-09-07.

Revenue by business segment

How AMGN’s $36.8B of revenue for the fiscal year 2025-01-01 to 2025-12-31 splits across what it sells, as the company tags it in its own 10-K.

Fiscal year ended 2025-12-31
SegmentShareRevenue
Other products 19.8% $7.3B
Prolia 12.0% $4.4B
Repatha 8.2% $3.0B
Otezla 6.2% $2.3B
ENBREL 6.1% $2.2B
EVENITY 5.7% $2.1B
XGEVA 5.7% $2.1B
TEPEZZA 5.2% $1.9B
Other revenues 4.4% $1.6B
BLINCYTO 4.2% $1.6B
Nplate 4.2% $1.5B
TEZSPIRE 4.0% $1.5B
KYPROLIS 3.8% $1.4B
Aranesp 3.8% $1.4B
KRYSTEXXA 3.6% $1.3B
Vectibix 3.2% $1.2B

These are the company’s own segment names and figures. They do not say whether a line of business is permissible; our business-activity screen does.

Source: 10-K filed 2026-02-13 (accession 0000318154-26-000010), read from its XBRL on SEC EDGAR. Shares are of total revenue; subtotals and overlapping cuts the filing also tags are left out, so the lines add up to the total.

What would change the status

The headline verdict is the majority of the decided ratio standards — 4 pass and 3 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-16.

Within 3 points of the line

Dow Jones Islamic, MSCI Islamic M-Series, S&P Shariah are within 3 points of their line. If they all crossed, the majority verdict would move from Compliant to Not compliant.

The ratios that move with the share price

AAOIFI's debt ratio is $54.0B debt over a market cap of $251.9B (as of 2026-11-16), 21.4% against a 30% line.

At the 2026-11-18 close the market cap is about $244.5B (the stored cap moved by the share price since), so this ratio would read 22.1%; the line is -26% from there. The published status changes only when the company is re-screened.

It would fail if the market cap fell to $180.0B (-29%), about $332.81 a share against $465.67 implied by the screen's own figures.

AAOIFI would then fail, and the majority verdict would move from Compliant to Not compliant (3 of 7 decided standards passing).

At the screen's market cap, debt would have to rise by $21.6B to reach the line.

AAOIFI would then fail, and the majority verdict would move from Compliant to Not compliant (0 of 7 decided standards passing, counting every standard that divides the same figure).

AAOIFI's investments ratio (5.2% against a 30% line) would only fail if the market cap fell by 83%, to $44.0B. At the 2026-11-18 close it would read 5.4%.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Drug Manufacturers - General listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
LLYLilly(Eli) & Co $1.2T —
JNJJohnson & Johnson $658.0B —
ABBVAbbvie Inc $467.4B —
MRKMerck & Co Inc $371.7B —
NVSNovartis AG - ADR $306.5B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold AMGN

21 of the 196 funds whose filed holdings we currently hold own AMGN shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns AMGN.

You may already own it

Widely held U.S. index funds. If you own one, you own AMGN through it. None of them is a Shariah fund; the last column is our look-through of each.

FundAMGN in fundFund compliant by weight
SCHD Schwab U.S. Dividend Equity ETF 4.70% 59%
DIA 4.36% 46%
QQQ Invesco QQQ Trust, Series 1 0.85% 69%
VYM VANGUARD HIGH DIVIDEND YIELD INDEX FUND 0.78% 46%
IWF iShares Russell 1000 Growth ETF 0.41% 69%
SCHB Schwab U.S. Broad Market ETF 0.31% 53%
VOO VANGUARD 500 INDEX FUND 0.30% 56%
SPY 0.30% 56%
SPYM State Street(R) SPDR(R) Portfolio S&P 500(R) ETF 0.30% 56%
IVV iShares Core S&P 500 ETF 0.30% 56%
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.27% 54%
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.27% 54%
RSP Invesco S&P 500 Equal Weight ETF 0.22% 44%
Other funds
FundAMGN in fundFund compliant by weight
SUPCX DWS Equity Sector Strategy Fund 0.65% 52%
PTMCX PGIM Quant Solutions Large-Cap Core Fund 0.50% 51%
VONG VANGUARD RUSSELL 1000 GROWTH INDEX FUND 0.49% 67%
RGACX Growth Fund of America 0.42% 54%
TISAX Nuveen S&P 500 Index Fund 0.32% 53%
STOX Horizon Core Equity ETF 0.29% 52%
FZROX Fidelity ZERO Total Market Index Fund 0.29% 51%
RNPHX New Perspective Fund 0.13% 57%

Sorted by AMGN’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names AMGN once, so a bond is not counted as the shares; 1 more fund name AMGN in a way we cannot separate from its bonds, and is not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding AMGN
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $1,051M 0.1% 2026-09-30
Ken Fisher Fisher Asset Management $713M 0.2% 2026-09-30
Israel Englander Millennium Management $489M 0.2% 2026-09-30
David Shaw D. E. Shaw & Co. $213M 0.1% 2026-09-30
Jefferies Jefferies Financial Group $63M 0.5% 2026-09-30
Paul Tudor Jones Tudor Investment Corp $55M 0.1% 2026-09-30
Ray Dalio Bridgewater Associates $48M 0.2% 2026-09-30
Joel Greenblatt Gotham Asset Management $39M 0.1% 2026-09-30
David Katz Matrix Asset Advisors $35M 2.9% 2026-09-30
Torray Investment Partners Torray Investment Partners $23M 3.1% 2026-09-30
Steven Cohen Point72 Asset Management $9M 0.0% 2026-09-30
Dodge & Cox Dodge & Cox $5M 0.0% 2026-09-30
Azzad Asset Management Azzad Asset Management $4M 0.4% 2026-09-30
Jeff Auxier Auxier Asset Management $4M 0.5% 2026-09-30
John Hussman Hussman Strategic Advisors $3M 0.6% 2026-09-30
Mairs & Power Mairs & Power $2M 0.0% 2026-09-30
Mario Gabelli GAMCO Investors $2M 0.0% 2026-09-30
Sallie Krawcheck Ellevest $1M 0.2% 2026-09-30
Lee Ainslie Maverick Capital $1M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

478.48435.75393.02350.29307.562025-11-192026-05-212026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
442.35
S2
447.69
S1
452.81
PIVOT
458.15
R1
463.27
R2
468.61
R3
473.73

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
383.15 – 446.07
±7.59% from 414.61, made 2026-09-26 · resolves 2026-10-03
STRONG BUY
from 19 indicators
77.1% of our last 20463 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.1% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

SELL
19 indicators
OscillatorsSELL
2 buy · 2 neutral · 3 sell
Moving averagesNEUTRAL
6 buy · 0 neutral · 6 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)45.70NEUTRAL
Stochastic %K (14)5.34BUY
CCI (20)-94.54NEUTRAL
Williams %R (14)-94.66BUY
MACD (12,26,9)-3.21SELL
ROC (10)-7.23SELL
Momentum (10)-34.59SELL
EMA (10)458.92SELL
SMA (10)461.61SELL
EMA (20)454.76SELL
SMA (20)458.95SELL
EMA (30)448.48SELL
SMA (30)447.55SELL
EMA (50)437.22BUY
SMA (50)428.15BUY
EMA (100)415.65BUY
SMA (100)412.43BUY
EMA (200)385.27BUY
SMA (200)380.25BUY

About AMGN

Healthcare · Drug Manufacturers - General

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

amgen.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Verdict

⚪ NEUTRAL — No Edge

Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.

Scores: 2 bullish / 2 bearish

Grade verdict

No real edge — avoid

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 64
⏰ 4H BEARISH 50
🕐 1H BEARISH 98
⏱ 15-Min RANGING 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-5.5%
Rate of change (10d)
2.3×
Volume vs its 20-day average
7.82
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

CLUSTER SELL   0 buys · 6 sells

Recent: Miller Derek sold 12462 sh @ $402.54 (2026-08-06); Miller Derek sold 12462 sh @ $402.54 (2026-08-06); Grygiel Nancy A. sold 7340 sh @ $402.16 (2026-08-06)

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.